The women’s competition will kick off with quarter‑final matches featuring India against Japan, Bangladesh versus China, Sri Lanka facing Malaysia, and Pakistan taking on Thailand. These matches are scheduled from September 17 to 22. The men’s tournament, running from September 24 to October 1, will open with Group A comprising Afghanistan, Japan, and Nepal, and Group B consisting of Hong Kong, Malaysia, and Oman. The top two teams from each group will advance to the knockout stage, where they will meet the teams that have already qualified directly.
![Phase 3 EPCORE DLBCL-1 Trial for Epcoritamab Fails to Achieve Primary Endpoint</TITLE]Genmab A/S (GMAB) and AbbVie Inc. (ABBV) announced on Thursday that the Phase 3 EPCORE DLBCL-1 trial, which evaluated Epcoritamab in adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival (OS) in the United States.](https://i2.wp.com/www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?w=1024&resize=1024,1024&ssl=1 "Phase 3 EPCORE DLBCL-1 Trial for Epcoritamab Fails to Achieve Primary Endpoint</TITLE]Genmab A/S (GMAB) and AbbVie Inc. (ABBV) announced on Thursday that the Phase 3 EPCORE DLBCL-1 trial, which evaluated Epcoritamab in adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival (OS) in the United States.")
